FindAPhD Weekly PhD Newsletter | JOIN NOW FindAPhD Weekly PhD Newsletter | JOIN NOW

Exploiting the effects of low mural cell β3-integrin in the control of cancer progression, therapy resistance and metastasis


   Barts and The London School of Medicine and Dentistry

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Prof K Hodivala-Dilke, Dr Stuart McDonald  No more applications being accepted  Funded PhD Project (UK Students Only)

About the Project

The project will commence in September 2022 and has funding for 3 years. The student will be based primarily at the Barts Cancer Institute, Barts and the London School of Medicine and Dentistry (SMD), Charterhouse Square in the City of London. This PhD studentship is funded by Cancer Research UK.

This exciting project will tackle the problem of improving treatment for cancer patients who need it most and understanding the basic biology behind this.

Most solid cancer related deaths are a result of resistance to therapy and metastasis. There is an urgent need to identifying patients who have a high risk of progression to determining alternative treatment strategies. Cells that constitute tumour blood vessels (BVs), including perivascular, supporting mural cells can control these processes.

We have discovered that loss of mural-cell β3-integrin stimulates intracellular signalling pathways resulting in paracrine signals that enhance primary tumour growth without affecting vascularisation. In human cancers, from different stages of progression, low mural β3-integrin expression is associated not only with an increase in cancer size (Wong and Muñoz-Félix et al., Cell 2020) but also with higher cancer stage, relapse rates and enhanced metastasis. These fundamental findings indicate a new mechanism of cancer growth regulation by mural cell β3-integrin with relevance to cancer progression and metastasis.

The successful applicant will learn a range of molecular, cellular and in vivo techniques in laboratory models and in human cancer in order to exploit the molecular mechanisms regulated by mural β3-integrin that specifically promote treatment resistance and metastasis to provide the best potential targets for therapeutic intervention. This exciting project is embedded in the heart of the Hodivala-Dilke Lab at the Barts Cancer Centre, part of the CRUK-City of London partnership with Kings College London, University College London and the Francis Crick Institute. The PhD will involve a multidisciplinary approach using state of the art techniques via cross institute collaborations.


Funding Notes

The studentship includes the following funding for 3 years:
- A tax-free annual stipend of £21,000
- Tuition fees at the Home rate*
- Project consumables
*If you are considered an overseas student for fee purposes, you are welcome to apply for this studentship, however you will be required to cover the difference in tuition fees.

How good is research at Queen Mary University of London in Clinical Medicine?


Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities
Search Suggestions
Search suggestions

Based on your current searches we recommend the following search filters.

PhD saved successfully
View saved PhDs